Trials / Completed
CompletedNCT05068752
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
A Phase II Trial of Vemurafenib in Combination With Sorafenib to Treat Patients With Advanced KRAS Mutated Pancreatic Cancer: Targeting RAF Dimers to Suppress Oncogenic RAS Signaling (The Dr. Nate Nieto Study)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- HonorHealth Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vemurafenib | Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID |
| DRUG | Sorafenib | Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily |
Timeline
- Start date
- 2021-10-28
- Primary completion
- 2024-11-08
- Completion
- 2024-12-13
- First posted
- 2021-10-06
- Last updated
- 2026-03-30
- Results posted
- 2026-03-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05068752. Inclusion in this directory is not an endorsement.